BMRN
Biomarin Pharmaceutical IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$10.81B
P/E Ratio
31.23
EPS
$1.80
Beta
0.29
52W High
$66.28
52W Low
$50.76
50-Day MA
$58.35
200-Day MA
$56.54
Dividend Yield
—
Profit Margin
10.80%
Forward P/E
10.98
PEG Ratio
0.65
About Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San Rafael, California.
Fundamentals
| Revenue (TTM) | $3.22B |
| Gross Profit (TTM) | $1.70B |
| EBITDA | $722.89M |
| Operating Margin | 22.50% |
| Return on Equity | 5.94% |
| Return on Assets | 5.58% |
| Revenue/Share (TTM) | $16.80 |
| Book Value | $31.65 |
| Price-to-Book | 1.75 |
| Price-to-Sales (TTM) | 3.36 |
| EV/Revenue | 3.017 |
| EV/EBITDA | 16.96 |
| Quarterly Earnings Growth (YoY) | 124.30% |
| Quarterly Revenue Growth (YoY) | 17.00% |
| Shares Outstanding | $192.32M |
| Float | $191.21M |
| % Insiders | 0.44% |
| % Institutions | 101.18% |
Analyst Ratings
Consensus ($88.87 target)
4
Strong Buy14
Buy5
HoldData last updated: 4/7/2026